Volltext-Downloads (blau) und Frontdoor-Views (grau)
The search result changed since you submitted your search request. Documents might be displayed in a different sort order.
  • search hit 1 of 3
Back to Result List

The art of virtualizing pharma R&D

  • Today, virtualizing pharma R&D is increasingly related with data analytics and artificial intelligence (AI), technologies that have been developed by software companies outside the healthcare sector. The process of virtualizing pharma R&D is closely related to the technological advancements that result in the generation of large data sets ranging from genomics, proteomics, metabolomics, medical imaging, IoT wearables and large clinical trials, making it necessary for pharma companies to find new ways to store and ultimately analyze information. As a consequence, pharma companies are experimenting with AI in R&D ranging from in-silico drug design to clinical trail participants identification or dosage error reduction.

Export metadata

Additional Services

Search Google Scholar

Statistics

frontdoor_oas
Metadaten
Author of HS ReutlingenSchuhmacher, Alexander
DOI:https://doi.org/10.1016/j.drudis.2019.07.004
Erschienen in:Drug discovery today
Publisher:Elsevier
Place of publication:Amsterdam
Document Type:Journal article
Language:English
Publication year:2019
Volume:24
Issue:11
Page Number:3
First Page:2105
Last Page:2107
DDC classes:610 Medizin, Gesundheit
Open access?:Nein
Licence (German):License Logo  In Copyright - Urheberrechtlich geschützt